Cellceutix begins trial of oral Prurisol in treating chronic plaque psoriasis

Cellceutix Corporation has begun screening patients for a phase 2b clinical trial of oral Prurisol for treating moderate-to-severe chronic plaque psoriasis, according to a press release.

Prurisol is a novel dermatology compound in mid-stage development as an oral psoriasis treatment.

The trial is a randomized, double-blind, multi-center study of more than 180 patients, with treatment groups including oral Prurisol 300 mg per day, oral Prurisol 400mg per day, and placebo for 12 weeks and a follow-up 4 weeks after treatment.

The previous maximum level of Prurisol used in daily dosing was 200 mg during a phase 2 trial, which showed the drug candidate as a promising treatment for psoriasis. The Psoriasis Ara and Severity Index (PASI) will be used to evaluate primary efficacy in the current study. Secondary endpoints will also be added in the phase 2b study, according to the release.

“The start of this study is a key milestone for our psoriasis program, bringing us closer to the phase 3 registration program, and its results will further build upon the positive Phase 2 data reported earlier this year,” Arthur P. Bertolino, MD, PhD, MBA, Cellceutix president and chief medical officer, stated in the release.

Cellceutix anticipates conducting an interim analysis of 6-week data from the study during the second quarter of 2017 and full study results in the third quarter of 2017, according to the release.

Reference: www.cellceutix.com